Compare Bristol-Myers Squibb Co (BMY) vs General Mills, Inc. (GIS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs General Mills, Inc. — how do they compare? Bristol-Myers Squibb Co trades at $58.45 (market cap $116.30B), while General Mills, Inc. trades at $36.91 (market cap $19.46B). The key difference: Bristol-Myers Squibb Co is far larger — about 6× General Mills, Inc.'s market cap, and General Mills, Inc. pays the higher dividend (6.69%). Which is the better fit depends on your goals.
| BMY | GIS | |
|---|---|---|
Market Cap | $116.30B | $19.46B |
Sector | Health | Consumer Staples |
52-Week High | $62.37 | $51.27 |
52-Week Low | $42.60 | $32.17 |
Enterprise Value | $152.24B | $32.95B |
Dividend Yield | 4.42% | 6.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
General Mills (GIS) trades at $36.60, up 1.05% with a bullish technical signal. The stock shows mixed earnings performance with recent Q2 2026 beating estimates, but faces declining revenue and negative net income margin. Analyst consensus is predominantly hold with a $36.14 price target. Cash flow trends show modest improvement, though debt levels have risen to 45% of assets. Recent news highlights cost-saving initiatives and innovation focus amid soft consumer demand.
Outlook remains cautious due to sales pressure and margin challenges, but valuation at 9.23 P/E suggests potential value. Key opportunities include $3 billion savings target by 2030 and brand investments. Risks involve persistent demand weakness, private label competition, and high debt burden. Investors should weigh cost-cutting benefits against top-line headwinds for recovery prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About General Mills, Inc.
General Mills is a leading global packaged food company that produces snacks, cereal, convenient meals, yogurt, dough, baking mixes and ingredients, pet food, and superpremium ice cream. Its largest brands are Nature Valley, Cheerios, Old El Paso, Yoplait, Pillsbury, Betty Crocker, BLUE, and Haagen-Dazs. In fiscal 2022, 77% of its revenue was derived from the United States, although the company also operates in Canada, Europe, Australia, Asia, and Latin America. While most of General Mills' products are sold through retail stores to consumers, the company also sells products into the food-service channel and the commercial baking industry.
Read more on GIS →
